1.Influencing factors on the choice of public or private hospitals by middle:Aged and elderly pa-tients
Chinese Journal of Health Policy 2015;(5):31-36
This paper uses the binomial logistic regression model and the 2011 China Health and Retirement Longitudinal Study ( CHALRS) to analyze the influencing factors on the choice of public or private hospitals by mid-dle-aged and elderly patients. The study finds that rural residents are significantly influenced by the self-evaluation of health, on-demand clinic consultation, and the use of basic medical insurance systems. There is a higher probability that patients that are not as healthy and that require clinical consultation or the use of the basic medical insurance sys-tem will choose public hospitals. The study concludes that elderly patients have greater trust in public hospitals when they seek treatment for disease risks. Moreover, the fixed points of medical insurance are concentrated in public hos-pitals, thereby prompting patients to choose public hospitals. It is suggested that the prevention and control of senile diseases be strengthened, the level of hospital consulting services be improved, and the access mechanisms of medi-cal insurance fixed point hospitals be adjusted.
2.On the Choice of the Chain Drug Store Mode from the Phenomenon of Franchise Returning to Direct Sales
China Pharmacy 2005;0(18):-
OBJECTIVE:To provide the reference for drug stores to choose the chain mode:the direct sales or franchise.METHODS:The common modes of the drug store’chain administration and the current condition of the chain drug store industry in china were summarized;The merits&demerits of each mode and the environment,which influenced the choice of chain modes,were analyzed.RESULTS&CONCLUSION:The phenomenon can not be the proof that direct sales are better than the franchise in the market.The Chinese pharmaceutical chain enterprises should make their own choices based on the specific situation.The improved franchise mode is very competitive in the market.
3.Preliminary Study on Pharmacoeconomics of Adverse Drug Reactions
China Pharmacy 2005;0(20):-
OBJECTIVE:To discuss the connotation,significance and methods of pharmacoeconomics of Adverse Drug Reactions(ADR).METHODS:The related studies evaluating the economic impact of ADR both at home and abroad were sum_ marized by literature review.RESULTS&CONCLUSION:There existed a big gap in the researches between China and foreign countries.Approaches to assessment of the economic costs of ADR were found to be cost study,cost-efficiency analysis of drug safety.The cost study includes the following3steps:defining ADR,estimating the incidence of ADR and measuring the costs of ADR.
4.Economic Efficiency of OEM on Drugs
China Pharmacy 2005;0(24):-
OBJECTIVE:To discuss the economic efficiency of original equipment manufacture(OEM)on drugs.METH?ODS:The economic efficiency of OEM on drugs was evaluated on the basis of transaction cost theory by analyzing the realistic and economic significance of OEM on pharmaceuticals and combining the current situation of supervision.RESULTS&CONCLUSION:The OEM on drugs should be encouraged at the proper time,by which the problem of repeated construction and low percentage of utilization of asset will be solved,and the rationalization of pharmaceutical industrial organization should be realized.
5.Pondering over Problems of Returning Drugs to Retail Drugstore from Customers
China Pharmacy 1991;0(03):-
OBJECTIVE:To provide suggestions for retail drugstores on how to tackle problems of non-quality induced drug returning from customers.METHODS:Reasons why it is hard to return the already purchased drugs were analyzed based on the status quo of drug returning in retail drugstores,and some countermeasures were presented on how to reduce or avoid non-quality induced drug returning problems.RESULTS&CONCLUSION:Non-quality induced drug returning problems can be well solved in drugstores through improving pharmaceutical care level and management level.
6.Discussion of Developing China as Clinical Research Center in Asian-Pacific Region
China Pharmacy 1991;0(04):-
OBJECTIVE:To provide reference for the development China as clinical research center in Asian-pacific re?gion.METHODS:To discuss the strengths,weaknesses,opportunities and threats of China as a regional clinical research center by analysis.RESULTS&CONCLUSION:Against the background of globalization of pharmaceutical research and development,expansion of the global clinical research markets provide great opportunities for China to develop its clinical re?search,and developing a good regulatory environment as well as improving the management of the clinical trial center will af?filiate China to be a competitive clinical research center in Asian-pacific region.
7.Study of the Related Problems in the Application of the Cost-effectiveness Analysis in Pharmacoeconomics
China Pharmacy 2001;0(11):-
OBJECTIVE:To probe into the related problems in the application of the cost-effectiveness analysis in pharmacoeconomics METHODS:To discuss the problems in the cost-effectiveness analysis by means of literature metrology,pharmacoeconomic criteria and mathematical proof RESULTS & CONCLUSION:When the cost-effectiveness analysis is adopted in evaluating the economy of drugs,we should especially pay attention to the selection of the clinical treatment indices,the calculation of costs,the usage of the incremental analysis and the comparison with the cost-minimization analysis
8.Evaluation of Competition among Branch Industries of Medical Manufacturers in Jiangsu Province by Using Shift-share Method
China Pharmacy 2001;0(08):-
OBJECTIVE:To provide the reference for industrial restructuring of pharmaceutical manufacturers in Jiangsu province.METHODS:Shift-share method was employed to analyze the competition among branch industries of pharmaceutical manufacturers in Jiangsu province.RESULT&CONCLUSION:The competitiveness of branch industries ranks as follows:chemical preparation manufacturing industry,chemical crude drug manufacturing industry,Chinese crude drug and Chinese patent drug processing industry,biologic product manufacturing industry,and animal drug manufacturing industry.
9.Analyze the Drug Elasticity of Demand of Urban Residents through ELES Model
China Pharmacy 2001;0(09):-
OBJECTIVE:To analyze drug elasticity of demand of urban residents with quantitation.METHODS:Expand linear expenditure system(ELES)model was used to analyze sectional data of different kinds of consumption expenditure and the disposable income of urban residents in2003and to calculate the value of marginal consumption tendency,the elasticity value of demand income and the demand price.RESULTS&CONCLUSIONS:The changes of drugs price have little influence on drugs demand,for urban residents,drugs consumption belongs to necessary for life.
10. Expression of EphB4/EphrinB2 in human brain astrocytomas and its pathologic significance
Tumor 2007;27(8):651-654
Objective: To investigate the expressions of EphrinB2 and its receptor EphB4, microvessel density (MVD), and Ki-67 in human brain astrocytomas and explore their pathological significance. Methods: Expressions of EphB4/EphrinB2, MVD and Ki-67 were detected by tissue microarray and Maxvision shortcut immunohistochemical staining in 84 cases of human astrocytomas and 12 cases of traumatic brain tissues. Results: The difference was significant in expressions of EphB4/ EphrinB2, MVD and Ki-67 labeling index (LI) between human astrocytomas and controlled human traumatic brain tissues (P < 0.05). Expression of EphB4/EphrinB2, MVD and Ki-67 LI had positive cooelation with tumor grade. Ki-67 LI and MVD positively correlated with expressions of EphB4 or EphrinB2 protein (P <0. 05). Conclusion: There is a close correlation between expression of EphB4/ EphrinB2 and differentiation degree, tumor angiogenesis in human brain astrocytoma. The over-expressions of EphB4 and EphrinB2 play an important role in promoting tumor development and angiogenesis. EphB4/ EphrinB2, MVD, and Ki-67 are fine reference parameters to estimate malignancy degree and pathologic features of human brain astrocytomas.